Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.

Conclusions -Heretofore unknown effects of torcetrapib were revealed in immune and inflammatory functions. A protein-based risk score predicted harm from torcetrapib within just 3 months. A protein-based risk assessment embedded within a large proteomic survey may prove to be useful in the evaluation of therapies to prevent harm to patients. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00134264.
PMID: 28974520 [PubMed - as supplied by publisher]

Source: Circulation - October 3, 2017 Category: Cardiology Authors: Williams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P Tags: Circulation Source Type: research